Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sinco Pharmaceuticals Holdings Ltd. ( (HK:6833) ) has provided an update.
Sinco Pharmaceuticals Holdings Limited has scheduled a board meeting for 26 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the possible recommendation of a final dividend, a decision that could affect shareholder returns and signal management’s confidence in the company’s financial performance.
The announcement of the upcoming results review and dividend deliberation provides investors with a timeline for key financial disclosures and capital allocation decisions. Market participants will be watching the outcome for indications of Sinco Pharmaceuticals’ earnings momentum, cash generation, and overall financial health amid competitive pressures in the pharmaceutical industry.
The most recent analyst rating on (HK:6833) stock is a Sell with a HK$0.16 price target. To see the full list of analyst forecasts on Sinco Pharmaceuticals Holdings Ltd. stock, see the HK:6833 Stock Forecast page.
More about Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Limited is a Cayman Islands-incorporated company listed in Hong Kong that operates in the pharmaceuticals sector. The group is involved in the development, manufacturing, or distribution of pharmaceutical products, serving healthcare and medical markets primarily from its base in Sichuan, mainland China.
Average Trading Volume: 329,268
Technical Sentiment Signal: Sell
Current Market Cap: HK$378.1M
Find detailed analytics on 6833 stock on TipRanks’ Stock Analysis page.